x

Posted 17 January, 2024

Aravive, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:ARAV in a 8-K filed on 17 January, 2024.


  In addition, on January 12, 2024, the Company terminated the employment of each of Gail McIntrye, Ph.D., the Company's Chief Executive Officer and Rudy C. Howard, the Company's Chief Financial Officer, effective as of January 17, 2024. In connection with such terminations, on January 17, 2024, each of Dr. McIntyre and Mr. Howard entered into a Separation Agreement and Release (each a "Separation Agreement") with the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Aravive, Inc.
Health Care/Life Sciences • Biotechnology
Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company was founded on December 10, 2008 and is headquartered in Houston, TX.
Market Cap
N/A
View Company Details
Aravive, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 12, 2024, (i) Amato Giaccia, Ph.D., Peter T.C. Ho, M.D., Ph.D., John A. Hohneker, M.D., Sigurd C. Kirk and Michael W. Rogers, each provided notice of his decision to resign from the Board and all committees thereof, effective as of January 17, 2024, and (ii) Dr. Eshelman and Dr. McIntyre each provided notice of their decision to resign from the Board and all committees thereof, effective immediately after the filing of the Form 15 with the Securities and Exchange Commission (the "SEC").

 

In addition, on January 12, 2024, the Company terminated the employment of each of Gail McIntrye, Ph.D., the Company's Chief Executive Officer and Rudy C. Howard, the Company's Chief Financial Officer, effective as of January 17, 2024. In connection with such terminations, on January 17, 2024, each of Dr. McIntyre and Mr. Howard entered into a Separation Agreement and Release (each a "Separation Agreement") with the Company. Each Separation Agreement provides for the lump sum payment on January 17, 2024 of the severance benefits provided for in such executive's employment offer letter, an amount equal to one year of such executive's base salary, and Mr. Howard's Separation Agreement provides for a stipend to cover the cost of continued payments under COBRA for twelve months, as provided in his offer letter. Dr. McIntyre's Separation Agreement also provides that Dr. McIntyre will provide consulting services to the Company, at no further cost, as may be required in connection with the liquidation of the Company and that in such capacity, Dr. McIntyre shall serve as the Company's Secretary and Authorized Officer.

 

The foregoing description of the Separation Agreement with Dr. McIntyre and the Separation Agreement with Mr. Howard does not purport to be complete and is qualified in its entirety by reference to each Separation Agreement, which are filed as Exhibits 10.2 and 10.3 to this Current Report on Form 8-K.

 


1